

**FOOD AND DRUG ADMINISTRATION (FDA)**  
Center for Drug Evaluation and Research (CDER)

*Dermatologic and Ophthalmic Drugs Advisory Committee Meeting*

HILTON WASHINGTON DC /ROCKVILLE  
ROCKVILLE, MARYLAND

QUESTIONS TO THE ADVISORY COMMITTEE

December 5, 2008

---

**Bimatoprost Ophthalmic Solution, Allergan**

1. Do you think the benefits outweigh the risks for Latisse (bimatoprost ophthalmic solution) 0.03% for the treatment of hypotrichosis of the eyelashes?
2. If not, what additional studies should be performed?
3. If so, should any additional Phase 4 studies should be performed?
4. Do you have any suggestions concerning the labeling of the product?

**FOOD AND DRUG ADMINISTRATION (FDA)**  
Center for Drug Evaluation and Research (CDER)

***Dermatologic and Ophthalmic Drugs Advisory Committee Meeting***

HILTON WASHINGTON DC /ROCKVILLE  
ROCKVILLE, MARYLAND

QUESTIONS TO THE ADVISORY COMMITTEE

December 5, 2008

---

**Besifloxacin HCl Ophthalmic Suspension, Bausch and Lomb, Inc.**

- 1) Do you think besifloxacin hydrochloride ophthalmic suspension should be approved for the treatment of bacterial conjunctivitis?
- 2) If not, what additional studies should be performed?
- 3) Do you have any suggestions concerning the labeling of the product?